Table 1.
Clinico-pathological features of the analysed tumour cases
| Case | Histology | Fusion status | Primary site | Clinical stage |
|---|---|---|---|---|
| ARMS1* | alveolar | PAX3 | trunk | III |
| ARMS2* | alveolar | PAX3 | extremity | III |
| ARMS3* | alveolar | negative | trunk | II |
| ARMS4* | alveolar | PAX7 | uterus-vagina | III |
| ARMS7 | alveolar | PAX3 | extremity | IV |
| ARMS36 | alveolar | PAX3 | trunk | III |
| ARMS37 | alveolar | PAX3 | uterus-vagina | II |
| ERMS1* | embryonal | n.a. | retroperitoneum | III |
| ERMS2* | embryonal | n.a. | bladder-prostate | III |
| ERMS3* | embryonal | n.a. | bladder-prostate | III |
| ERMS4* | embryonal | n.a. | trunk | III |
| ERMS12 | embryonal | n.a. | bladder-prostate | III |
| ERMS21 | embryonal | n.a. | retroperitoneum | III |
| ERMS23 | embryonal | n.a. | uterus-vagina | II |
| ERMS27 | embryonal | n.a. | extremity | I |
Variables were categorized as follows: histological subtype, embryonal versus alveolar; gene fusion status; primary site and clinical stage. Fusion status PAX3: PAX3-FOXO1–positive; PAX7: PAX7-FOXO1–positive ; n.a. - not applicable. The symbol * indicates samples used for deep sequencing analysis.